Plus Therapeutics Announces New Chief Development Officer
AUSTIN, Texas — Plus Therapeutics, Inc. (NASDAQ: PSTV), a clinical-stage pharmaceutical company focused on innovative radiotherapeutics, is thrilled to announce the appointment of Dr. Michael Rosol as Chief Development Officer. Dr. Rosol's extensive expertise will significantly bolster the company's commitment to developing advanced treatment options for central nervous system (CNS) cancers.
The Expertise of Dr. Michael Rosol
Dr. Michael Rosol brings over 25 years of rich experience in clinical trial design and regulatory execution to Plus Therapeutics. His illustrious career recently included a role as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Before that, he played a pivotal role at Novartis Pharmaceuticals, where he led important biomarker development and translational imaging initiatives. With a Ph.D. in biomedical and radionuclide imaging from Boston University, Dr. Rosol has also held esteemed academic positions at top institutions such as Harvard Medical School, Mayo Clinic, and the Medical University of South Carolina.
Comments from Company Leadership
In light of this significant appointment, Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics, remarked, "We are at a crucial juncture in our clinical development, transitioning from mid-stage to pivotal trials. Mike’s extensive background in oncology complements our goals perfectly, aligning with the stages of our clinical pipeline. His insights and leadership will undoubtedly drive our mission forward.”
The Vision for Plus Therapeutics
Dr. Rosol expressed enthusiasm about joining Plus Therapeutics, highlighting, "This is an exciting time to join the team. The current pipeline and the recent clinical outcomes demonstrate considerable promise for severe CNS cancers. My background aligns well with our strategies towards achieving FDA approval, and I am eager to contribute to this important work.”
Understanding the Challenges in CNS Cancer Treatments
Leptomeningeal Metastases (LM) represents a rare yet severe consequence of cancer, resulting from the spread of primary tumors to the cerebrospinal fluid. This condition complicates treatment, with limited approved therapies available for patients. Additionally, Glioblastoma (GBM), the most common and aggressive brain cancer, remains a significant hurdle in oncology. With high rates of recurrence and limited treatment options, the need for innovative therapies is urgent.
About Plus Therapeutics, Inc.
Plus Therapeutics is dedicated to developing targeted radiotherapeutics aimed at combating challenging cancers of the central nervous system. By employing advanced techniques that combine beta radiation with targeted drug delivery, the company is advancing several promising product candidates focusing primarily on recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Through strategic partnerships, Plus Therapeutics has effectively established a supply chain to facilitate the development and potential commercialization of its innovative solutions. The company operates in key hubs for cancer clinical development, with a profound commitment to enhancing patient outcomes.
Investor Relations Contact
For further information, interested parties can reach out to Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations, via:
- Office: (202) 209-5751
- Direct: (301) 728-7222
- Email: chuang@plustherapeutics.com
Frequently Asked Questions
Who is Dr. Michael Rosol?
Dr. Michael Rosol is the newly appointed Chief Development Officer at Plus Therapeutics, with extensive experience in oncology and clinical trial design.
What is Plus Therapeutics focused on?
Plus Therapeutics specializes in developing targeted radiotherapeutics for central nervous system cancers, including glioblastoma and leptomeningeal metastases.
What does the appointment of Dr. Rosol mean for Plus Therapeutics?
His appointment is expected to drive the company's clinical development forward as it transitions from mid-stage to pivotal trials.
How does Leptomeningeal Metastases affect cancer patients?
Leptomeningeal Metastases complicates cancer treatment and significantly reduces survival outcomes, highlighting the need for targeted therapies.
Where can I find more information about Plus Therapeutics?
For more details, you can visit the official website of Plus Therapeutics.
